GLP1R and type 2 diabetes mellitus: GLP-1 receptor agonists (GLP-1 RAs) have been approved for the treatment of T2DM since 2005 and are recommended, as per the latest guidelines, early in the treatment algorithm given the associated weight reduction, glycemic efficacy, and favorable cardio-nephrovascular outcomes [7, 8].